| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-083 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 经 2024 年年度股东会审议，同意授权董事会决定公司 2025 年中期股 息派发方案，本预案无需提交股东会审议。 一、 利润分配方案内容 根据 2025 年半年度财务报告（未经审计），公司 2025 年半年度实现归属 于母公司净利润 880,045,883.20 元，2025 年半年度末可供股东分配的利润为 5,761,758,753.44 元。经董事会审议，公司 2025 年半年度利润分配方案如下： 公司拟向全体股东每股派发现金红利 0.30 元（含税）。截至 2025 年 6 月 30 日 ， 公 司 总 股 本 1,212,416,854 股 ， 以 此 计 算 合 计 拟 派 发 现 金 红 利 363,725,056.20 元（含税），本次公司拟派发的现金分红总额占公司 2025 年半 年度实现的归属于上市公司股东的净利润的比例为 41.33%。 关于 2025 年半年度利润分配预案的 ...

格隆汇8月28日丨益丰药房(603939.SH)公告称，益丰药房发布2025年半年度报告，2025年上半年营业收 入为117.22亿元，同比下降0.35%；公司实现归属于母公司净利润8.8亿元，同比增长10.32%。公司拟以 权益分派股权登记日的总股本为基数，向全体股东每股派发现金红利0.30元（含税）。 ...

益丰大药房连锁股份有限公司2025 年半年度报告 公司代码：603939 公司简称：益丰药房 益丰大药房连锁股份有限公司 2025 年半年度报告 1 / 195 益丰大药房连锁股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人高毅、主管会计工作负责人王永辉及会计机构负责人（会计主管人员）管长福 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司2025年半年度实现归属于母公司净利润880,045,883.20元，2025年半年度末可供股东分配 的利润为5,761,758,753.44元。 公司拟以2025年半年度权益分派股权登记日的总股本为基数，向全体股东每股派发现金红利 0.30元（含税），不送红股，不进行资本公积金转增股本。预计派发现金股利363,725,056.20元（ 含税）。如在董事会审议通过本预案之日起 ...

Core Viewpoint - The company reported a slight decline in revenue for the first half of 2025, while net profit showed a positive growth trend [1] Financial Performance - The company's operating revenue for the first half of 2025 was 11.722 billion yuan, representing a year-on-year decrease of 0.35% [1] - The net profit for the same period was 880 million yuan, reflecting a year-on-year increase of 10.32% [1] Dividend Distribution - The company plans to distribute a cash dividend of 0.30 yuan per share (including tax) to all shareholders based on the total share capital as of the dividend record date for the first half of 2025 [1] - The total cash dividend payout is expected to be 364 million yuan (including tax) [1]

Core Viewpoint - The financial performance of the leading chain pharmacy, Lao Bai Xing, has shown a decline in both revenue and net profit for the first half of 2025, indicating challenges in the retail pharmacy sector amid increased competition and operational changes [1][3]. Financial Performance - In the first half of 2025, the company achieved revenue of 10.774 billion yuan, a year-on-year decrease of 1.51% [1]. - The net profit attributable to shareholders was 398 million yuan, down 20.86% compared to the previous year [1]. - The gross profit margin for the main business was 33.08%, a decline of 1.24 percentage points year-on-year [1]. Store Expansion and Market Strategy - The company is actively expanding into lower-tier markets, with 87% of new stores opened in cities below the prefecture level during the first half of 2025 [2]. - As of the end of the reporting period, stores in cities below the prefecture level accounted for 77% of the total store count [2]. - The number of franchise stores increased by 457, reaching a total of 5,601 [2]. Management Changes - The company experienced significant management turnover in 2025, with both the president and vice president resigning [2]. - The founder, Xie Zilong, has taken on the roles of both chairman and president following these departures [2]. - The high turnover rate in the executive team has raised concerns about stability, with multiple resignations noted in recent years [2]. Overall Industry Context - The overall performance of major listed chain pharmacies, including Lao Bai Xing, has been declining, with a notable drop in revenue and net profit for the year 2024 [3]. - The company’s major shareholder announced a significant share reduction plan, which was partially executed before being terminated [3]. - From June 20 to July 30, 2025, the major shareholder reduced their holdings by 18.11 million shares, amounting to 2.38% of the total shares, generating over 340 million yuan in cash [3].

Policy Developments - The National Medical Products Administration (NMPA) has released multiple registration review guidelines for cancer screening in vitro diagnostic reagents, aiming to further standardize the management of these products [1] Medical Device Approvals - Sinno Medical announced that its subsidiary received a medical device registration certificate for a disposable microcatheter, which will enhance its product portfolio in the neurointerventional sector [2] - Heng Rui Medicine received approval for clinical trials of HRS-6093 tablets, a novel oral KRASG12D inhibitor, and HRS-2162 injection, a new generation muscle relaxant antagonist, both of which currently have no similar products approved in the market [3] - Mayinglong's subsidiary obtained a drug registration certificate for Olopatadine Hydrochloride eye drops, used for treating allergic conjunctivitis [4] Financial Reports - Xiaofang Pharmaceutical reported a 3.06% year-on-year increase in revenue to 270 million yuan and a 1.69% increase in net profit to 121 million yuan for the first half of the year [5] - Renhe Pharmaceutical's revenue decreased by 16.46% to 1.975 billion yuan, with a net profit decline of 13.87% to 290 million yuan for the same period [6] - China National Pharmaceutical Group announced a revenue of 286 billion yuan and an operating profit of 7.45 billion yuan for the first half of the year, with a gross margin of 7.11% [7] Capital Market Activities - BeiGene entered into a royalty purchase agreement with Royalty Pharma, agreeing to pay $885 million for the rights to a significant portion of royalties from the monoclonal antibody Imdelltra outside of China [9] - Terumo Corporation announced a $1.5 billion acquisition of OrganOx to expand its presence in the transplant medicine sector, focusing on liver preservation technology [10] Industry Developments - A domestic team has successfully utilized brain-computer interface technology for precise diagnosis and treatment of hydrocephalus, significantly reducing diagnosis time from 2-3 days to 30 minutes, marking a breakthrough in the application of this technology [11] - Sailun Biotech has launched its rabies serum product for sale in several provinces, becoming the only company to market this product [12] Corporate News - Yifeng Pharmacy announced the resignation of its Vice President, Zhang Jia, due to personal reasons [13]

Meeting Overview - The second extraordinary general meeting of shareholders was held on August 25, 2025, at the Yifeng Pharmaceutical Logistics Park in Changsha, Hunan Province [2] - The meeting was conducted through a combination of on-site and online voting, presided over by Chairman Gao Yi, and complied with relevant laws and regulations [2][3] Attendance - All 9 current directors and 3 current supervisors attended the meeting, along with the board secretary and some other senior executives [3] Resolutions Passed - The following proposals were approved during the meeting: 1. Proposal to abolish the supervisory board and amend the Articles of Association [4] 2. Proposal to amend the Board Meeting Rules [5] 3. Proposal to amend the Independent Director Work System [5] 4. Proposal to amend the External Guarantee Management System [5] 5. Proposal to amend the External Investment Management System [5] 6. Proposal to amend the Shareholders Meeting Rules [5] 7. Proposal to amend the Related Party Transaction Management System [5] 8. Proposal to amend the Fundraising Management System [6] 9. Proposal to add a system for the resignation of directors and senior management [6] 10. Proposal for the company to provide guarantees for bank credit applications by subsidiaries [6] Special Resolutions - Three special resolutions, including the proposal to abolish the supervisory board, received more than two-thirds approval from the shareholders present [6] Employee Representative Director Election - An employee representative meeting was held on August 25, 2025, where Gao Youcheng was elected as the employee representative director, with a term lasting until the end of the fifth board's term [7][8] Senior Management Departure - Vice President Zhang Jia submitted a resignation report due to personal reasons and will not hold any other positions within the company post-resignation [11] - The company has made arrangements to ensure that Zhang Jia's departure will not affect normal operations, and the board expressed gratitude for his contributions during his tenure [12]

Meeting Details - The shareholders' meeting was held on August 25, 2025, at Yifeng Pharmaceutical Logistics Park, Changsha, Hunan Province [1] - The meeting was attended by shareholders representing 74.5997% of the total shares [1] - The voting method combined on-site and online voting, and the meeting was presided over by Chairman Gao Yi [1] Voting Results - All proposed resolutions were approved with significant majority votes, including: - A resolution received 99.9676% approval from A-shareholders [1] - Another resolution had 90.5251% approval, with 9.4664% against [1] - A different resolution garnered 93.4949% approval, with 6.4965% against [1] - Additional resolutions also received over 90% approval from A-shareholders [2] Legal Compliance - The meeting's procedures complied with the Company Law and relevant regulations, ensuring the legality of the meeting and voting results [2]

本律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东会规则》（以下简称"《股东会规则》"） 等我国现行法律、法规、规范性文件以及《益丰大药房连锁股份有限公司章程》 （以下简称"《公司章程》"）的有关规定出具本法律意见书。 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 关于益丰大药房连锁股份有限公司 法律意见书 二O二五年八月 致：益丰大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）接受益丰大药房连锁股份有限公 司（以下简称"公司"）的委托，指派本律师出席了公司 2025 年第二次临时股东 会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人 员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见 ...

金融界消息 截至2025年8月25日收盘，益丰药房（603939）报收于24.13元，下跌1.67%，换手率 1.24%，成交量15.05万手，成交金额3.62亿元。 资金流向方面，今日主力资金净流出5898.46万元，占比成交额16.28%。其中，超大单净流出3851.99万 元、占成交额10.63%，大单净流出2046.48万元、占成交额5.65%，中单净流出流入1805.76万元、占成 交额4.98%，小单净流入4092.70万元、占成交额11.3%。 来源：金融界 天眼查商业履历信息显示，益丰大药房连锁股份有限公司，成立于2008年，位于常德市，是一家以从事 卫生为主的企业。企业注册资本121243.2297万人民币，实缴资本12000万人民币。公司法定代表人为高 毅。 通过天眼查大数据分析，益丰大药房连锁股份有限公司共对外投资了33家企业，参与招投标项目1316 次，知识产权方面有商标信息311条，专利信息6条，此外企业还拥有行政许可126个。 益丰药房最新一期业绩显示，截至2025一季报，公司营业总收入60.09亿元、同比增长0.64%，归属净利 润4.49亿元，同比增长10.51%，扣非净利润4 ...